Navigation Links
ChanTest Introduces the CardioChannelGram™ and SaVety Assessment
Date:4/16/2013

Cleveland, OH (PRWEB) April 16, 2013

Determining the drug-induced inhibition of the cardiac hERG potassium channel is recommended by both the International Conference on Harmonization (ICH) and the US Food and Drug Administration (FDA) in order to predict delayed cardiac repolarization (DR) and cardiac risk. However, extending this determination to actually identifying drugs that may cause TdP, a serious polymorphic ventricular tachycardia, has been challenging.

In response to this need, ChanTest has introduced the CardioChannelGram™ - cardiac ion channel profiling plus logistic regression models that predict DR and TdP risk. Predictivity is significantly better when quantitative drug effects on Cav1.2 and Nav1.5 ion channels, in addition to hERG, are measured. Cardiac risk can now be characterized earlier in development than ever before using automated patch clamp platforms.

“ChanTest is pleased to be responding to the industry's needs by introducing this new line of testing to the drug discovery community,” said Arthur "Buzz" Brown, Ph.D., M.D., CEO, President and founder. “Our new CardioChannelGram™ and SaVety Assessment will provide greater insight into potential cardiac risk, allowing more effective decision-making in early preclinical development.”

Click here to learn more about the ChanTest CardioChannelGram™ and SaVety Assessment.

FURTHER INFORMATION
ChanTest
14656 New Parkway
Cleveland, Ohio 44128
1-877-828-1777 Toll Free
1-216-332-1665 Tel
1-216-332-1706 Fax
info(at)chantest(dot)com

Contact for Media Inquiries:

Chris Mathes, Ph.D., M.B.A.
Chief Commercial Officer
cmathes(at)chantest(dot)com
http://www.chantest.com

About ChanTest® – The Ion Channel Expert

ChanTest’s mission is to serve the drug discovery and development needs of customers worldwide with high-value solutions for ion channel and GPCR biology. Since its inception in 1998, the CRO has tested compounds for more than 500 global pharmaceutical and biotechnology companies, and partners with them to speed the drug development process for the release of better, safer drugs.

ChanTest offers integrated ion channel and GPCR services (GLP and non-GLP) and reagents; the company’s library of validated ion channel cell lines, and nonclinical cardiac risk assessment service portfolio, is the most comprehensive commercially available today.

Because of ChanTest’s seminal role in the nonclinical cardiac safety field, along with the company’s uncompromising commitment to quality, ChanTest has been named the “most trusted and most used fee-for-service provider” for ion channel screening in an independent survey for the past several years. ChanTest is based in Cleveland, Ohio.

Visit http://www.chantest.com to learn more about what we do.

Read the full story at http://www.prweb.com/releases/2013/4/prweb10634495.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. ChanTest Announces Their Second User Meeting: Partnerships in Drug Discovery
2. ChanTest Announces a Complimentary Webinar on the Use of the xCELLigence System
3. Diagenode Introduces Innovative Bioruptor® Pico for Micro-Volume Chromatin and DNA Shearing
4. Texas Fertility Center Introduces Oncofertility Education Program for Physicians and Patients
5. Finesse Solutions Introduces SmartParts for Intelligent Universal Controllers
6. Cearna Introduces Product Designed to Reduce Patient’s Recovery Time From Facial Plastic Surgery
7. Rigaku Introduces New Instruments at Pittcon 2013
8. GIN Introduces Advanced Robotics and Dispensing Technology at BVS La Jolla Biotech Day
9. FMC BioPolymer Introduces Its New Portfolio of Nature-Based Nutritional Solutions
10. Percival Scientific, Inc. Introduces an Affordable LED Lighting System for the Research Industry
11. Palomar Medical Center in San Diego County Introduces New Wrist-Worn Wireless Patient Vital Signs Device
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... ... States multicenter, prospective clinical study that demonstrates the accuracy of the FebriDx® ... identifying clinically significant acute bacterial and viral respiratory tract infections by testing ...
(Date:10/11/2017)... N.C. (PRWEB) , ... October 11, 2017 , ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the co-founder, ... ( ASTER Labs ), Inc. has been selected for membership in ARCS ...
(Date:10/11/2017)... BALTIMORE, Md. (PRWEB) , ... October 11, 2017 ... ... for digital pathology, announced today it will be hosting a Webinar titled, “Pathology ... of  Advanced Pathology Associates , on digital pathology adoption best practices and how ...
(Date:10/11/2017)... ... October 11, 2017 , ... A ... pregnancy rates in frozen and fresh in vitro fertilization (IVF) transfer ... age to IVF success. , After comparing the results from the fresh and ...
Breaking Biology Technology:
(Date:5/23/2017)... 23, 2017  Hunova, the first robotic gym for the rehabilitation and ... launched in Genoa, Italy . The first 30 robots ... the USA . The technology was developed and patented ... the IIT spin-off Movendo Technology thanks to a 10 million euro investment ... please click: ...
(Date:4/19/2017)... , April 19, 2017 ... its vendor landscape is marked by the presence of ... is however held by five major players - 3M ... these companies accounted for nearly 61% of the global ... leading companies in the global military biometrics market boast ...
(Date:4/11/2017)... BEACH GARDENS, Fla. , April 11, 2017 ... identity management and secure authentication solutions, today announced ... contract by Intelligence Advanced Research Projects Activity (IARPA) ... for IARPA,s Thor program. "Innovation has ... onset and IARPA,s Thor program will allow us ...
Breaking Biology News(10 mins):